BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
The company impresses investors, but money’s running short.
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.
